Patents Assigned to PureTech Management, Inc.
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20200338130
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 29, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20200318071
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: March 10, 2020
    Publication date: October 8, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20200138869
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: August 28, 2019
    Publication date: May 7, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20200093865
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: December 3, 2019
    Publication date: March 26, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard